trial

Efficacy Study of Switching Stabilized Schizophrenic Patients From Conventional to Atypical Antipsychotic Treatment

NCTId NCT00191555
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 360
Sponsored by Eli Lilly and Company
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
360
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2003-08
Primary completion
—
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
OlanzapineHaloperidol

Sponsors

Eli Lilly and CompanyLead Sponsor

Investigators

1
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)Study Director

Sites

62 total
Aix-en-Provence, FranceAlençon, FranceAlise-Sainte-Reine, FranceAmilly, FranceAubergenville, FranceBarbazan-Debat, FranceBohars, FranceBordeaux, FranceBourges, FranceBron, FranceBrumath, FranceCastres, France

Facts & assertions

3 sourced
Enrollment
360
Phase
PHASE4
Status
COMPLETED
relationships
The graph out of here
drug
Olanzapine
drug
Haloperidol
drug
lead_sponsor
Eli Lilly and Company
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)
person